A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
暂无分享,去创建一个
A. Oza | I. Ray-Coquard | Byoung-Gie Kim | T. Herzog | J. Sehouli | O. Petrenciuc | N. Colombo | G. Scambia | M. Shan | J. Markowska | C. Lhommé